Sound waves could open Brain's barrier to fight deadly tumor
NCT ID NCT07562971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new way to treat a rare and aggressive brain tumor called diffuse midline glioma (DMG) in the brainstem. The approach uses MRI-guided focused ultrasound to temporarily open the blood-brain barrier, allowing more of the chemotherapy drug temozolomide to reach the tumor. The trial will include 20 children and adults and aims to see if the procedure is safe and whether it can slow tumor growth or extend survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
temozolomide
What this could lead to
If it works, this could improve how well chemotherapy reaches and attacks this hard-to-treat brain tumor, potentially slowing its growth and extending survival.
What could go wrong
This is a very early, small pilot study with only 20 participants. The technique may not work as hoped, and there are risks from the ultrasound procedure and chemotherapy side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE MIDLINE GLIOMA, H3 K27-ALTERED are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Princess Maxima Center for pediatric oncology
Utrecht, 3584 CS, Netherlands
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UMC Utrecht
Utrecht, 3584 CX, Netherlands
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact